1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

J INTS BIO & MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001'

26 Nov 2024
Admin
News Article

J INTS BIO & MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001'

J INTS BIO and MD Anderson Collaborate on the Development of Brain Tumor Treatment 'JIN-001' - Enhancing Radiation and Chemotherapy Efficacy

Overview

J INTS BIO announced research findings on its innovative brain tumor treatment, 'JIN-001,' developed in collaboration with MD Anderson Cancer Center, at the 2024 Society of Neuro-Oncology (SNO) Annual Meeting in Texas, USA. MD Anderson is a globally renowned cancer research institution, and J INTS BIO has partnered with it since 2021 to advance this groundbreaking therapy.

JIN-001: Aiming to Revolutionize Brain Tumor Treatment

JIN-001' targets glioblastoma (GBM) cells by significantly enhancing the efficacy of radiation therapy and chemotherapy.
As a selective inhibitor of HSP90 (Heat Shock Protein 90), its primary advantage lies in its ability to cross the blood-brain barrier (BBB), which typically hinders therapeutic agents from reaching the brain.
While the BBB serves as a protective mechanism for the brain, it also presents a major obstacle for drug delivery.
JIN-001 overcomes this limitation, directly attacking brain tumors and addressing the low permeability issue of existing drugs.
The study also highlighted that JIN-001 demonstrated promising results when combined with standard therapies such as Radiation Therapy and Temozolomide, effectively suppressing tumor cell growth and inducing apoptosis (programmed cell death).

JIN-001: Pioneering Future Clinical Developments

Based on these promising findings, J INTS BIO plans to accelerate preclinical trials for JIN-001.
The company intends to incorporate CRISPR gene-editing technology to identify the functional roles of specific genetic factors in treatment resistance, paving the way for precision medicine strategies.
CRISPR-based techniques allow targeted modulation of gene expression, helping to predict and better understand tumor responses.

Commercialization of JIN-001

J INTS BIO is also advancing plans to commercialize JIN-001 through partnerships with global pharmaceutical companies, aiming to bring faster and more effective treatments to brain tumor patients.
Furthermore, the potential applications of JIN-001 are being explored in treating a wide range of cancers beyond brain tumors, providing new hope for cancer patients worldwide.

About JIN-001

JIN-001 represents a groundbreaking innovation that transcends the limitations of existing therapies, offering new treatment opportunities and hope for improved survival and quality of life for brain tumor patients.